Curaleaf (OTCMKTS:CURLF – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.25, Zacks reports. The company had revenue of $340.10 million during the quarter, compared to the consensus estimate of $332.00 million. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.89%.
Curaleaf Stock Up 0.9%
Shares of Curaleaf stock traded up $0.08 during trading hours on Friday, reaching $9.30. 59,648 shares of the company’s stock were exchanged, compared to its average volume of 312,624. The stock has a market cap of $2.17 billion, a P/E ratio of -71.53 and a beta of 1.56. The company has a 50 day moving average of $7.02 and a two-hundred day moving average of $7.69. The company has a current ratio of 1.56, a quick ratio of 0.74 and a debt-to-equity ratio of 1.05. Curaleaf has a fifty-two week low of $5.22 and a fifty-two week high of $15.15.
Analyst Ratings Changes
Several research firms have issued reports on CURLF. Citigroup reissued a “buy” rating on shares of Curaleaf in a research note on Thursday. Zacks Research raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Strong Buy”.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Featured Stories
- Five stocks we like better than Curaleaf
- AST SpaceMobile’s Latest BlueBird Launch Raises the Stakes Ahead of Q2 Earnings
- Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of Truth
- IonQ Sparks a Quantum Grid Revolution
- No Hangover: Revisiting Microsoft One Week After Earnings
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
